Loading…

Ambea ABAMBEA.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Medical/Nursing Services

Nordic provider of care services for the elderly and people with disabilities, operating group homes and care facilities.

≈ A Nordic elderly/disability care operator like a smaller Genesis HealthcareMomentum leader 82
Mkt cap
$1.59B
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$3.04M
20-day average traded
Fwd P/E
15.2×
forward earnings
ROIC−WACC
+1.2 pp
WACC 5.3%
Hurdle
-7 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · SEKSEK 192.10
1D-1.6%
1W-1.7%
1M+4.7%
3M+9.7%
6M+27.6%
YTD+36.0%
1Y+49.7%
ATR %2.3%
52w lowhigh2.7% off high

What Ambea does

Nordic provider of care services for the elderly and people with disabilities, operating group homes and care facilities.

In one line: A Nordic elderly/disability care operator like a smaller Genesis Healthcare.

Products and services

  • Elderly care homes
  • Disability support services
  • Individual/family care services

Customers

  • Municipalities (payers)
  • Care recipients and families

Where it sits in the supply chain

  • Health Care
  • Care services
  • Elderly and disability residential/care…

What could go right

  • Aging Nordic population driving care demand
  • Municipal outsourcing of care services

What could go wrong

  • Public reimbursement rate/policy risk
  • Staffing shortages and wage inflation

Moat: narrow (regulatory licence, scale, installed base). Licensed care-provider status and scale in a publicly funded, contract-based Nordic welfare model.

Headquarters: Stockholm, Sweden · Founded: 2001 · Employees: 41,118

Named competitors

  • Attendo ATT.ST
  • Humana (private) private or unlisted
  • Vardaga (private) private or unlisted

Ambea at a glance

Size Ambea (AMBEA.ST) is a Sweden Health Care company (Medical/Nursing Services) with a market value of $1.59B, the 98th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 192.10 on 18 Nov 2026.

Performance Over six months the shares gained 27.6%, against +14.0% for the median peer and +2.8% for the Sweden market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 11.4% over the last twelve months (peer median +9.2%); the operating margin is 8.8% (peer median 3.2%).

Valuation It trades at 15.2× forward earnings against a peer median of 33.5× (2nd cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.2 points above its cost of capital (5.3% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026AMBEA.ST 127Peer median 111
Six months, rebased to 100: Ambea against the median of its 20 peers (local-currency closes).

Ambea financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 17.2BSEK 16.0BSEK 14.2BSEK 13.3BSEK 12.6B
Revenue growth—+13%+7%+5%—
Gross profitSEK 1.51BSEK 2.70BSEK 2.44BSEK 2.08BSEK 1.89B
EBITDASEK 3.13BSEK 2.71BSEK 2.48BSEK 1.95BSEK 1.61B
Net incomeSEK 846MSEK 665MSEK 620MSEK 455MSEK 366M
Free cash flowSEK 2.33BSEK 2.05BSEK 1.96BSEK 1.63BSEK 1.34B
Capital expenditureSEK 149MSEK 139MSEK 117MSEK 90.0MSEK 105M
Total debtSEK 13.8BSEK 12.6BSEK 10.8BSEK 10.7BSEK 11.0B

Quarterly statements and history in the cockpit →

Ambea competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%SNDAPSNLWGSAGLVIJAYA300244TDOC4544USPHEMEIS1833AGARWALEYELMRICLARINEODIAPNTGOPKMETROPOLISAMBEA.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Ambea is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%20×40×60×80×WGSAGLVIJAYA3002444544USPH6038821833AGARWALEYELMRICLARINEODIAPNTGMETROPOLISAMBEA.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ambea is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%VIJAYA300244TDOC4544USPHEMEIS603882AGARWALEYECLARIDIAPNTGMETROPOLISAMBEA.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ambea is the large dot.

Ambea competitors and peer comparison

Head to head with its named competitors (AMBEA.ST vs ATT.ST)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ambea AMBEA.ST$1.59B+28%+11%9%15.2×1.1%
Attendo ATT.ST$1.87B+15%0%10%16.9×1.7%

How Ambea compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ambea against its 20 peers (data as of 18 Nov 2026)
MeasureAMBEA.STPeer medianRank in peer set
1-month return+4.7%-0.3%8th highest of 21
6-month return+27.6%+14.0%6th highest of 21
Distance from 52-week high-2.7%-24.1%2nd highest of 21
Revenue growth (TTM)+11.4%+9.2%9th highest of 21
Operating margin8.8%3.2%6th highest of 21
Forward P/E15.2×33.5×2nd cheapest of 16
Growth the price implies (Req g, 7 yrs)1.1%9.7%3rd least demanding of 14
Growth delivered (Del g)+7.7%+10.5%6th lowest of 14
Hurdle (Req g minus delivered)-6.5 pp+7.6 pp3rd least demanding of 14
ROIC minus cost of capital+1.2 pp-4.4 pp5th highest of 20
EV / EBITDA9.6×20.4×4th cheapest of 13
Net debt / EBITDA4.4×2.8×7th most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%63.0×40.4%+16.7%
Dian Diagnostics 300244.SZChina$1.70B+1%-5%9%21.8×0.3%-1.1%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%n/a21.2%+8.5%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%29.9×5.4%-6.1%
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%77.1×43.0%+26.9%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
NeoGenomics NEOUnited States$1.98B+72%+11%-6%53.5×n/an/a
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%

Questions

Who are Ambea's main competitors?
Named competitors: Attendo (ATT.ST), Humana (private) (private or unlisted), Vardaga (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Sonida Senior Living (SNDA), Personalis (PSNL), GeneDx (WGS), agilon health (AGL), Vijaya Diagnostic Centre (VIJAYA.NS), Dian Diagnostics (300244.SZ).
Is Ambea expensive compared with its peers?
On forward p/e it trades at 15.2× against a peer median of 33.5×, 2nd cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Ambea stock performed?
Over six months to 18 Nov 2026 the shares returned +27.6% against +14.0% for the median peer; over one year +49.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.